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Abstract
Introduction: The aim of this study was to explore the use of dexmedetomidine as a safe and efficacious sedative
agent in post-cardiac surgery patients.
Methods: A systematic literature search of MEDLINE, EMBASE, the Cochrane Library and Science Citation Index
until January 2012 and review of studies was conducted. Eligible studies were of randomized controlled trials or
cohort studies, comparing dexmedetomidine with a placebo or an alternative sedative agent in elective cardiac
surgery, using dexmedetomidine for postoperative sedation and available in full text. Two reviewers independently
performed study selection, quality assessment, and data extraction.
Results: The search identified 530 potentially relevant publications; 11 met selection criteria in this meta-analysis.
Our results revealed that dexmedetomidine was associated with a shorter length of mechanical ventilation (mean
difference -2.70 [-5.05, -0.35]), a lower risk of delirium (risk ratio 0.36 [0.21, 0.64]), ventricular tachycardia (risk ratio
0.27 [0.08, 0.97]) and hyperglycemia (risk ratio 0.78 [0.61, 0.99]), but may increase the risk of bradycardia (risk ratio
2.08 [1.16, 3.74]). But there was no significant difference in ICU stay, hospital stay, and morphine equivalents
between the included studies. Dexmedetomidine may not increase the risk of hypotension, atrial fibrillation,
postoperative nausea and vomiting, reintubation within 5 days, cardiovascular complications, postoperative
infection or hospital mortality.
Conclusions: Dexmedetomidine was associated with shorter length of mechanical ventilation and lower risk of
delirium following cardiac surgery. Although the risk of bradycardia was significantly higher compared with
traditional sedatives, it may not increase length of hospital stay and hospital mortality. Moreover, dexmedetomidine
may decrease the risk of ventricular tachycardia and hyperglycemia. Thus, dexmedetomidine could be a safe and
efficacious sedative agent in cardiac surgical patients.
Keywords: Bradycardia, Hypotension, Delirium, Mechanical ventilation, Intensive care unit, Sedation
Introduction
Sedation, used to reduce stress response and provide
anxiolysis [1], is an important component of postoperative
management following cardiac surgery. The ideal sedative
for use after cardiac surgery would have an immediate
onset of action, be effective at providing immediate resolu-
tion of the agitation and anxiety, allow rapid recovery after
discontinuation, lack drug accumulation, have minimal
adverse effects, and be cost-effective [1,2]. However, no
single agent or combination of agents has shown a clear
superiority to meet these clinical standards [3].
Dexmedetomidine is a highly selective and potent cen-
tral a2-receptor agonist which binds to transmembrane G
protein-binding adrenoreceptors, and has no activity on
the g-aminobutyric acid (GABA) system [4]. By decreasing
central nervous system sympathetic outflow, dexmedeto-
midine has analgesic effects known as opioid-sparing [5].
This property is unique among sedatives used in the inten-
sive care unit (ICU) because it produces sedation and
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analgesia without causing respiratory depression [6]. In
addition, the use of a2-agonists has been associated with
lower cardiovascular complications in high-risk non-car-
diac surgery [7].
Approved by the US Food and Drug Administration in
2008, dexmedetomidine represents only 4% of the drugs
used for adult sedation outside of the operating room [8].
Currently, in Europe and the United States, benzodiaze-
pines and propofol are the commonly used sedative
agents in the ICU [3,9]. A recent systematic review
stressed the use of dexmedetomidine as an alternative for
postoperative sedation in critically ill adult patients [10].
The authors demonstrated that dexmedetomidine
reduces the length of ICU stay compared with traditional
sedative agents such as propofol, midazolam and mor-
phine. From the clinician’s viewpoint, dexmedetomidine
has a favorable profile, as it can facilitate weaning from a
mechanical ventilator by not depressing spontaneous
ventilation. However, hypotension and bradycardia, the
most common adverse effects of dexmedetomidine, have
limited its use in the ICU. Concerns that these side
effects could influence hemodynamic stability and
increase hospital mortality have led to controversy
regarding the benefits and risks of dexmedetomidine in
postoperative sedation. Thus, the primary goal of the cur-
rent study was to explore the use of dexmedetomidine as
a safe and efficacious sedative agent following cardiac
surgery.
Materials and methods
Search strategy and selection of studies
Two researchers independently carried out a comprehen-
sive literature search. The literature search was conducted
in January 2012 using multiple databases including
EMBASE, MEDLINE, the Cochrane Library and Science
Citation Index, from January 1979 through January 2012.
A basic search was performed using keywords: ‘dexmede-
tomidine’ AND (’cardiac surgery’ OR ‘coronary artery
bypass grafting’ OR ‘heart surgery’ OR ‘heart valve’ OR
‘cardiopulmonary bypass’) AND (’sedation’ OR ‘sedative’).
In addition, we reviewed abstracts from selected major
cardiac surgical scientific meetings (American Heart Asso-
ciation, American Association for Thoracic Surgery,
European Association for Cardio-Thoracic Surgery, and
Asian Society for Cardiovascular Surgery) for unpublished
studies, and contacted the authors for detailed information
if needed. Our searches were restricted to English lan-
guage studies for convenience reasons. To be eligible for
inclusion in this article, publications met the following
four inclusion criteria: (1) original research comparing
dexmedetomidine with a placebo or an alternative sedative
agent in elective cardiac surgery patients aged over 18
years; (2) study design: randomized controlled trial (RCT),
non-randomized controlled trial or cohort study; (3)
studies that continued use of dexmedetomidine for post-
operative sedation for more than 6 hours, and not used for
anesthesia in the operating theater, and (4) availability of
full text (detailed information).
Data abstraction and quality assessment
The two reviewers who extracted the data were blinded to
the journal names and authors. If there were any differ-
ences in data abstraction or quality assessment, then the
differences were reconciled by a third reviewer. The fol-
lowing information was abstracted and tabulated from
each paper: author and year of publication; design; number
of patients; surgery type; sedation goal and dose of dexme-
detomidine, and placebo or alternative sedative agent. The
following outcomes were extracted if reported: duration of
mechanical ventilation; length of ICU stay; morphine
equivalents; length of hospital stay; mortality at hospital
discharge; risk of bradycardia or hypotension requiring
interventions; risk of delirium; ventricular tachycardia;
atrial fibrillation; hyperglycemia; nausea and vomiting;
reintubation within 5 days after extubation, and any post-
operative infection. If there was incomplete reporting of
clinical outcomes in any of the articles, we attempted to
contact the authors to obtain additional information. For
example, given that virtually all patients were intubated for
surgery, not all studies reported the mean value and stan-
dard deviation of the length of mechanical ventilation. We
contacted authors [11-13] for additional detail on the out-
comes mentioned above; however, no additional informa-
tion was added. A ratio of relative risks and difference
between treatment agents for categorical and continuous
outcomes respectively, were extracted from all publica-
tions (if presented). Categorical outcomes are reported as
risk ratio (RR) and corresponding 95% confidence interval
(95% CI), while continuous outcomes are reported as
weighted mean difference (MD). A P-value < 0.05 was
used to determine statistical significance.
Quality assessment was undertaken independently by
two authors (Table 1). The quality of included studies
was evaluated based on a well established, validated
Newcastle-Ottawa Scale (http://www.ohri.ca/programs/
clinical_epidemiology/oxford.htm). Differences were
resolved by discussion and consensus, and if disagree-
ment still persisted, the opinions of all members of the
research team were sought.
Statistical analysis
Where outcomes of interest were reported by two or
more studies, effect estimates were combined with meta-
analyses in Review Manager (Version 5.1., The Cochrane
Collaboration, 2011). Statistical heterogeneity between
trials was evaluated by the Cochran c2 statistic, and was
considered to be significant when the P-value for hetero-
geneity was ≤ 0.1. When statistical heterogeneity was
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observed, a random-effect model was used for the analy-
sis. In the absence of statistically significant heterogeneity
(P-value for heterogeneity > 0.1), only the fixed-effect
model was utilized. Potential publication bias or small
study bias was examined by visual inspection of con-
structed funnel plots.
To further test the robustness of the results, several sen-
sitivity analyses were performed a priori. First, we evalu-
ated whether the model of the statistical method (random-
effect vs. fixed-effect model) would change the results; sec-
ond, we determined whether the quality of publication,
high quality (RCT) or low quality studies (retrospective
cohort), could influence the results of the meta-analysis.
Moreover, subgroup analysis was performed according to
different criteria (for example, different sedative agents,
high and low dose of dexmedetomidine). Where data were
not presented in a way that could be included in the meta-
analysis, or where only one study was identified for a given
outcome, results of individual studies were presented.
Results
Included studies
A total of 530 studies were retrieved in the literature
search, including 233 articles in MEDLINE, 146 articles in
EMBASE, 3 articles in the Cochrane Library, and 148 arti-
cles in the Science Citation Index. After a check for dupli-
cates and removal of reviews, 257 publications remained
eligible for inclusion in the meta-analysis (Figure 1). Of
these, the abstracts were screened for dexmedetomidine,
sedation and cardiac surgery, and 204 publications were
removed for non-cardiac surgery. Among the remaining
53 eligible studies, 13 publications were removed because
the studies did not report on dexmedetomidine and post-
operative sedation. Eleven papers were excluded because
they included infant or pediatric cardiac surgery, six
papers reported only the outcomes of dexmedetomidine
and did not compare outcomes with a placebo or an alter-
native sedative agent, five papers were excluded because
they reviewed the use of dexmedetomidine in the ICU but
failed to report any outcomes, five were excluded for use
of anesthesia in the operating theater, and two were
excluded for not being published in English. Thus, 11
papers were included in the meta-analysis.
Description of the included papers
Table 2 presents details of the included studies. Study
designs included three randomized control trials, four
prospective cohort studies and four retrospective stu-
dies. The smallest study contained 28 cardiac surgery
patients (Aziz, et al.), whereas the largest study included
10,352 patients (Dasta, et al.). Eight studies compared
dexmedetomidine with alternative hypnotic agents
(seven studies with propofol [12-18], three with midazo-
lam [16,17,19], and one with lorazepam [17]). Two stu-
dies compared dexmedetomidine with morphine [11,20].
The remaining study compared three drugs (dexmedeto-
midine, and propofol plus midazolam) with two drugs
(propofol plus midazolam) [21].
Outcomes of the pooled studies
Meta-analysis of nine studies [11,14-21] revealed that
dexmedetomidine significantly reduced the length of
mechanical ventilation (MD -2.70, 95% CI -5.05, -0.35,
P = 0.02) (Figure 2A). Our results found dexmedetomi-
dine treatment did not appear to reduce the length of
ICU stay (MD -3.44, 95% CI -11.40, 4.52, P = 0.40)
[15,16,18,20], length of hospital stay (MD -0.28, 95% CI
-0.64, 0.07, P = 0.36) [15-17,20,21], or morphine equiva-
lents (MD 0.45, 95% CI -1.86, 2.77, P = 0.70)
[13,15,16,18] compared with other sedatives (Additional
File 1). There was significant heterogeneity between the
pooled studies in the length of mechanical ventilation,
length of ICU stay and morphine equivalents. Thus, a
random-effect model was used for these three analyses.
When pooled, dexmedetomidine was found to signifi-
cantly increase the risk of bradycardia (RR 2.08, 95% CI
1.16, 3.74, P = 0.01) (Figure 2B), but not hypotension (RR
1.06, 95% CI 0.72, 1.56, P = 0.60) (Figure 2C). Addition-
ally, dexmedetomidine reduced the incidence of delirium
following cardiac surgery (RR 0.36, 95% CI 0.21, 0.64, P =
0.0004) (Figure 3A). Sedation with dexmedetomidine was
associated with a lower risk of ventricular tachycardia
(RR 0.27, 95% CI 0.08, 0.97, P = 0.04) (Figure 3B) and
Table 1 Quality score of included studies
Study included Newcastle-Ottawa Scale*
1 2 3 4 5A 5B 6 7 8
1 Herr (2003) Yes Yes Yes Yes Yes Yes Yes Yes Yes
2 Anger (2010) Yes Yes Yes Yes Yes Yes Yes Yes Yes
3 Yapici (2010) Yes Yes Yes Yes No Yes Yes Yes Yes
4 Barletta (2009) Yes Yes Yes No No Yes Yes Yes Yes
5 Maldonado (2009) Yes Yes Yes Yes Yes Yes Yes Yes Yes
6 Dasta (2006) Yes Yes Yes No No No No Yes Yes
7 Aziz (2011) Yes Yes Yes Yes Yes Yes Yes Yes Yes
8 Shehabi (2009) Yes Yes Yes Yes Yes Yes Yes Yes Yes
9 Wunsch (2010) Yes Yes Yes No No No No Yes Yes
10 Corbett (2005) Yes Yes Yes Yes Yes Yes Yes Yes Yes
11 Reichert (2011)# Yes Yes Yes Yes Yes Yes Yes Yes Yes
*1 indicates exposed cohort truly representative; 2, non-exposed cohort drawn
from the same community; 3, ascertainment of exposure; 4, outcome of
interest not present as start of study; 5A, cohort comparable on basis of
sedation goal level; 5B, cohort comparable on other factor(s); 6, quality of
outcome assessment; 7, follow-up long enough for outcomes to occur; and 8,
complete accounting for cohorts. #For case-control study, 1 indicates cases
independently validated; 2, cases are representative of population; 3,
community control; 4, controls have no history of cardiac surgery; 5A, study
control for sedation goal level; 5B, study controls for additional factor(s); 6,
ascertainment of exposure by blinded interview or record; 7, same method of
ascertainment used for cases and controls; and 8, non-response rate the same
for cases and controls.
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hyperglycemia (RR 0.78, 95% CI 0.61, 0.99, P = 0.04)
(Figure 3C).
Dexmedetomidine was not associated with a significant
reduction of atrial fibrillation (RR 0.90, 95% CI 0.62, 1.29,
P = 0.56) [14,18,20], postoperative nausea and vomiting
(RR 1.02, 95% CI 0.72, 1.46, P = 0.91) [11,14,20] (Addi-
tional File 2). Furthermore, there was no effect of dexme-
detomidine on reintubation (RR 1.62, 95% CI 0.51, 5.13,
P = 0.41) [12,15,20], postoperative infection (RR 0.92,
95% CI 0.65, 1.29, P = 0.62) [14,18,20] or hospital mortal-
ity (RR 0.89, 95% CI 0.38, 2.12, P = 0.08) [15,17,18,20,21]
(Additional File 3). As to cardiovascular complications,
Herr et al. [14] found no difference in the incidence of
myocardial infarction (P = 0.371) and cardiac failure (P =
0.723) between dexmedetomidine and propofol, and
Yapici et al. [19] and Shehabi et al. [20] reported similar
incidence of postoperative low output syndrome (P =
0.093) and cardiac arrest (P = 0.513), respectively.
Publication bias and sensitivity analyses
Using the length of mechanical ventilation as an end-
point, the funnel plot implies the possibility of publica-
tion bias (Figure 4). This bias could be explained by the
following reasons: Barletta et al. [12] adopted a fast-track
recovery model, which was different from other included
articles, and it just needed shorter duration of mechanical
ventilation; Yapici et al. [19] enrolled patients who had
failed extubation and this caused longer-term ventilation
support. The sensitivity analysis shows that regardless of
which effect model was applied, the outcomes remained
similar (Table 3). Further, we excluded the four retro-
spective studies [12,13,17,21] and Yapici et al.[19], which
included the patients already presenting in a delirium
state. Table 4 shows that after excluding the five above-
mentioned studies, the outcomes still shared similarities
with the outcomes when all eleven studies were included.
Discussion
The current meta-analysis suggested that dexmedetomi-
dine is associated with shorter length of mechanical ven-
tilation, and lower risk of delirium, ventricular
tachycardia and hyperglycemia following cardiac surgery,
but that the risk of bradycardia was significantly higher
compared with traditional sedative agents.
With greater clinical use and knowledge regarding a2
characteristic conscious sedation, a sedative agent with-
out respiratory depression could hypothetically improve
weaning and shorten extubation times. Our results
showed that dexmedetomidine reduced the length of
mechanical ventilation; however, there was no significant
Figure 1 Flow of studies through the process of retrieval and inclusion in the meta-analysis.
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Surgery type Sedation goal Dexmedetomidine,
infusion rate
Control, infusion rate
1 Herr (2003) Randomized,
open label study
295 CABG§ RSS§ ≥ 3 during assisted ventilation and ≥ 2
after extubation
1.0 ug/kg over 20 minutes then 0.2
to 0.7ug/kg/h to maintain
Propofol: not given
2 Anger (2010) Prospective,
descriptive study
56 Cardiac surgery Similar RASS§ between groups 0.6 ± 0.1 ug/kg/h Propofol: 1.5 ± 0.6 ug/kg/h
3 Yapici (2010) Prospective
observational
study
72 Cardiac surgery Performing RASS scores at 48 and 60 h
postoperative
0.3 to 0.7 ug/kg/h Midazolam: 0.05 to 0.2 mg/kg/h
4 Barletta (2009) Retrospective
study
100 Cardiac surgery Not given 0.3 ± 0.12 ug/kg/h Propofol: 29 ± 11 ug/kg/min
5 Maldonado (2009) RCT§ 118 Cardiac surgery RSS of 3 before extubation and 2 after
extubation
loading dose: 0.4 ug/kg and then 0.2
to 0.7 ug/kg/h to maintain
Propofol: 25 to 50 ug/kg/min;
midazolam: 0.5 to 2.0 mg/h
6 Dasta (2006) Retrospective
study
10352 Cardiac valve and
vessel surgery
Not given Three drugs (dexmedetomidine,
propofol plus midazolam): not given
Two drugs (propofol plus
midazolam): not given
7 Aziz (2011) RCT 28 Cardiac surgery Modified Ramsay Score and Numeric Pain
Intensity Scale (compared within groups)
0.12 ± 0.03 ug/kg/h Morphine: 13.2 ± 5.84 ug/kg/h
8 Shehabi (2009) RCT 306 Pump cardiac
surgery
Motor Activity Assessment Scale of 2 to 4 0.1 to 0.7 ug/kg/h Morphine: 10 to 70 ug/kg/h
9 Wunsch (2010) Retrospective
cohort study
5332 CABG and valve
surgery
Not given Not given Midazolam, lorazepam,
propofol: not given
10 Corbett (2005) Prospective
randomized
study
89 CABG RSS of 5 for the first 2 h postoperative,
followed by a score of 3 to 4 during intubation
Loading dose:1 ug/kg over 15
minutes, followed by 0.4 ug/kg/h
Propofol: 5 to 75 ug/kg/min
11 Reichert (2011) Retrospective
case-control
study
70 CABG SAS§ targeted to scores of 3 or 4 0.3 to 0.7 ug/kg/h Propofol: 15 to 30 ug/kg/min












difference in the duration of ICU stay and hospital days
following cardiac surgery. Similar to previous reports
[10], we should interpret this result with caution, as there
was significant heterogeneity between the pooled studies
in the length of mechanical ventilation. This heterogene-
ity between the included studies could be attributed to
different mechanical ventilation weaning protocols, dif-
ferent study designs or publication bias. Compared with
commonly used sedatives, sedation with dexmedetomi-
dine was not associated with higher risk of reintubation
within 5 days after extubation. This meta-analysis pro-
vides evidence that with regard to duration of mechanical
ventilation, cardiac surgery patients may benefit from the
use of dexmedetomidine.
Our results also revealed that dexmedetomidine may
decrease the incidence of delirium in cardiac surgery
patients. The pathogenesis of delirium is not completely
clear, but onset appears to be related to drug binding at
the GABA receptor and release of deliriogenic mediators
[2]. With high and specific receptor selectivity, dexme-
detomidine does not bind to the GABA receptor and
hence has intrinsic delirium-sparing effects, including
asserting its sedative effects by blocking a single neuro-
transmitter, promoting cooperative sedation, producing
sedation without respiratory depression and providing a
more physiologic sleep-wake cycle. Moreover, it has
been reported that dexmedetomidine administration
causes the disappearance of delirium symptoms [19].
These reports are consistent with our study, suggesting
that dexmedetomidine could be a favorable choice for
the management of the delirium-state following cardiac
surgery. Furthermore, because the dose of sedatives is
determined by the level of sedation acquired, it would
be essential to use mandatory daily interruption of
Figure 2 Meta-analysis of postoperative mechanical ventilation, bradycardia and hypotension. (A) Meta-analysis of length of mechanical
ventilation (hours). (B) Meta-analysis of postoperative bradycardia. (C) Meta-analysis of postoperative hypotension.
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sedation to avoid over-sedation. Daily interruption of
sedation, especially early mobilization and fast-track
weaning protocols, have been shown to decrease the
incidence of delirium in cardiac surgery patients [22,23].
Thus, the use of dexmedetomidine, together with early
mobilization and fast-track weaning protocols may pro-
vide additional benefit for patients following cardiac
surgery.
The most frequently reported adverse events asso-
ciated with dexmedetomidine treatment are bradycardia
and hypotension [24]. In our study, use of dexmedeto-
midine was associated with increased risk of bradycar-
dia, but was not accompanied by increased risk of
systemic hypotension. Since the majority of the adverse
events associated with dexmedetomidine administration
occur during or shortly after the loading dose, it has
been recommended that using a lower loading infusion
rate during the first hour or eliminating the loading
dose, may reduce the incidence of hypotension [14].
Previously, it has been shown that overdose of dexme-
detomidine may cause first- or second-degree atrioven-
tricular block [25]. Thus, caution should be used in
sensitive patient populations, such as patients with left
ventricular dysfunction or severe heart block, where the
sympatholytic actions of a2 receptor agonists could
prove especially dangerous. While severe bradycardia
leading to cardiac arrest has been reported with the use
of dexmedetomidine [26-28], the incidence of cardiovas-
cular complications, including cardiac arrest after car-
diac surgery, has not been shown to be significantly
different compared with other sedatives. Further, our
results showed that sedation with dexmedetomidine
could reduce the risk of ventricular tachycardia com-
pared with propofol and morphine. Cardiac conduction
Figure 3 Meta-analysis of postoperative delirium, ventricular tachycardia and hyperglycemia. (A) Meta-analysis of postoperative delirium.
(B) Meta-analysis of ventricular tachycardia. (C) Meta-analysis of hyperglycemia.
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system dysfunction appears to be associated with use of
dexmedetomidine [29]. Additional studies are warranted
to investigate whether dexmedetomidine interferes with
postoperative cardiac conduction and to underscore the
value of adequate patient selection for the safe adminis-
tration of dexmedetomidine.
It had been demonstrated that dexmedetomidine had
opioid-sparing effects [30,31]. However, ICU sedation with
dexmedetomidine did not reduce morphine equivalents in
our analysis. Prior reports show that dexmedetomidine
has no apparent effect on blood glucose concentration
[4,32]. The current study reported the same outcome, that
the use of dexmedetomidine decreases the risk of hyper-
glycemia after cardiac surgery. Since postoperative hyper-
glycemia is associated with increased in-hospital mortality
in non-diabetic patients after cardiac surgery [33,34], this
property may help the clinicians to better control plasma
glucose levels after surgery.
However, there were some limitations in this meta-ana-
lysis. First, possible heterogeneity of study design, drugs,
dosing regimens and the postoperative recovery unit
model precluded meta-analysis of these study results.
Also, the publication bias of some results, for example,
length of mechanical ventilation, may affect the precision
of this outcome. Second, difficulty maintaining consistency
across studies is apparent when different goals for ideal
sedation were adopted; for example, some studies required
Ramsay level ≥ 3, while others used levels 2 to 4, 2 or 3, or
5. We highlight the need for a reliable and valid sedation
scoring system to improve the interpretability of future
studies. Thus, given that dexmedetomidine is currently
much more expensive than commonly used drugs (for
example, propofol), cost is becoming an increasingly criti-
cal factor in deciding whether to adopt new therapies. We
were not able to compare cost in these trials because
drug-related cost was not well-defined. Four, there was
lack of long-term follow-up in patients treated with dex-
medetomidine in the selected articles. Further studies are
needed to explore the long-term effect of dexmedetomi-
dine administration in cardiac surgery patients.
Figure 4 Funnel plot with length of mechanical ventilation as an endpoint. MD, mean difference; SE, Standard Error.
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Conclusions
In this meta-analysis, the most striking finding was that
sedation with dexmedetomidine is associated with
shorter length of mechanical ventilation and lower risk
of delirium following cardiac surgery. Although the risk
of bradycardia was significantly higher compared with
traditional sedative agents, bradycardia may not increase
the length of hospital stay and mortality at hospital dis-
charge. Moreover, dexmedetomidine may decrease the
risk of postoperative ventricular tachycardia and hyper-
glycemia. Thus, dexmedetomidine could be a safe and
efficacious sedative agent in cardiac surgery patients.
Further studies should underline the value of adequate
patient selection for the safe use of dexmedetomidine
following cardiac surgery.
Key Messages
1. Dexmedetomidine is a highly selective and potent
central a2-receptor agonist that produces sedation with-
out causing respiratory depression, which is unique
among sedatives used in the ICU. However, controver-
sies exit in regarding the benefits and risks of dexmede-
tomidine in postoperative sedation.
2. Use of dexmedetomidine was found to be associated
with shorter length of mechanical ventilation and lower
risk of delirium following cardiac surgery.
Table 3 Sensitivity analysis of outcomes according to the different effect models
Outcomes Fixed-effect model Random-effect model
Length of mechanical ventilation MD -1.39 (-2.04, -0.74) -2.70 (-5.05, -0.35)
Duration in ICU MD -0.22 (-1.85, 1.41) -3.44 (-11.40, 4.52)
Hospital stay MD -0.28 (-0.64, 0.07) -0.36 (-0.83, 0.11)
Morphine equivalents MD 1.11 (0.11, 2.11) 0.45 (-1.86, 2.77)
Hypotension RR 0.94 (0.80, 1.10) 0.99 (0.72, 1.36)
Bradycardia RR 2.08 (1.16, 3.74) 2.04 (1.12, 3.68)
Delirium RR 0.36 (0.21, 0.64) 0.39 (0.13, 1.19)
Ventricular tachycardia RR 0.27 (0.08, 0.97) 0.36 (0.07, 1.96)
Atrial fibrillation RR 0.90 (0.62, 1.29) 0.88 (0.62, 1.27)
Hyperglycemia RR 0.78 (0.61, 0.99) 0.78 (0.62, 0.99)
Vomiting and nausea RR 1.02 (0.72, 1.46) 1.02 (0.71, 1.46)
Reintubation within 48 hours RR 1.62 (0.51, 5.13) 1.51 (0.46, 4.96)
Any postoperative infection RR 0.89 (0.38, 2.12) 0.89 (0.30, 2.64)
Hospital mortality RR 0.79 (0.57, 1.09) 0.72 (0.37, 1.39)
MD: mean difference; RR: risk ratio. Values in parentheses are 95% CI.
Table 4 Subgroup analysis of outcomes according to study quality










6 -0.87 (-1.67, -0.07) 0.78 0.03
Duration in ICU 4 -3.44 (-11.40, 4.52) 0.03 0.40
Hospital stay 3 -0.38 (-0.95, 0.19) 0.11 0.20
Morphine equivalents 3 1.25 (-0.98, 3.49) 0.06 0.27
Hypotension 4 1.06 (0.72, 1.56) 0.001 0.78
Bradycardia 3 2.08 (1.16, 3.74) 0.42 0.01
Delirium 3 0.35 (0.19, 0.63) 0.06 0.0005
Ventricular tachycardia 3 0.27 (0.08, 0.97) 0.27 0.04
Atrial fibrillation 3 0.90 (0.62, 1.29) 0.67 0.56
Hyperglycemia 3 0.78 (0.61, 0.99) 0.98 0.04
Vomiting and nausea 3 1.02 (0.72, 1.46) 0.48 0.91
Hospital mortality 3 1.00 (0.28, 3.60) 0.17 1.00
Any postoperative infection 3 0.89 (0.38, 2.12) 0.29 0.80
Reintubation within 48 hours 2 1.21 (0.33, 4.41) /# 0.77
*Five studies excluded in this subgroup analysis: four [14,16,17,21] were retrospective studies and one [18] included the patients already presenting in a delirium
state. /#Heterogeneity was not applicable. Values in parentheses are 95% CI.
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3. Although the risk of bradycardia was significantly
higher compared with traditional sedatives, dexmedeto-
midine may not increase the length of hospital stay and
hospital mortality. Moreover, it may decrease the risk of
ventricular tachycardia and hyperglycemia.
4. Dexmedetomidine could be a safe and efficacious
sedative agent in cardiac surgery patients.
Additional material
Additional File 1: Figure showing meta-analysis of (A) ICU stay, (B)
hospital stay, and (C) morphine equivalents.
Additional File 2: Figure showing meta-analysis of (A) atrial
fibrilation, and (B) vomiting and nausea.
Additional File 3: Figure showing meta-analysis of (A) reintubation,
(B) postoperative infection, and (C) hospital mortality.
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